|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Massarweh NN and El-Serag HB: Epidemiology
of hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
Cancer Control. 24:10732748177292452017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bruix J, Gores GJ and Mazzaferro V:
Hepatocellular carcinoma: Clinical frontiers and perspectives. Gut.
63:844–855. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Guo H, Wu T, Lu Q, Li M, Guo JY, Shen Y,
Wu Z, Nan KJ, Lv Y and Zhang XF: Surgical resection improves
long-term survival of patients with hepatocellular carcinoma across
different Barcelona clinic liver cancer stages. Cancer Manag Res.
10:361–369. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cheng L, Wang C, Ma X, Wang Q, Cheng Y,
Wang H, Li Y and Liu Z: Multifunctional upconversion nanoparticles
for dual-modal imaging-guided stem cell therapy under remote
magnetic control. Advanced Functional Materials. 21:272–280. 2013.
View Article : Google Scholar
|
|
6
|
Huang M, Shen S, Luo C and Ren Y: Genus
periploca (Apocynaceae): A review of its classification,
phytochemistry, biological activities and toxicology. Molecules.
24:27492019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xie G, Sun L, Li Y, Chen B and Wang C:
Periplocin inhibits the growth of pancreatic cancer by inducing
apoptosis via AMPK-mTOR signaling. Cancer Med. 10:325–336. 2021.
View Article : Google Scholar
|
|
8
|
Yun W, Qian L, Cheng Y, Tao W, Yuan R and
Xu H: Periplocymarin plays an efficacious cardiotonic role via
promoting calcium influx. Front Pharmacol. 11:12922020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yun W, Qian L, Yuan R and Xu H:
Periplocymarin alleviates doxorubicin-induced heart failure and
excessive accumulation of ceramides. Front Cardiovasc Med.
8:7325542021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bloise E, Braca A, De Tommasi N and
Belisario MA: Pro-apoptotic and cytostatic activity of naturally
occurring cardenolides. Cancer Chemother Pharmacol. 64:793–802.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li Y, Li J, Zhou K, He J, Cao J, An M and
Chang YX: A review on phytochemistry and pharmacology of cortex
periplocae. Molecules. 21:17022016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Triana-Martínez F, Picallos-Rabina P, Da
Silva-Álvarez S, Pietrocola F, Llanos S, Rodilla V, Soprano E,
Pedrosa P, Ferreirós A, Barradas M, et al: Identification and
characterization of cardiac glycosides as senolytic compounds. Nat
Commun. 10:47312019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Guerrero A, Herranz N, Sun B, Wagner V,
Gallage S, Guiho R, Wolter K, Pombo J, Irvine EE, Innes AJ, et al:
Cardiac glycosides are broad-spectrum senolytics. Nat Metab.
1:1074–1088. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Prassas I and Diamandis EP: Novel
therapeutic applications of cardiac glycosides. Nat Rev Drug
Discov. 7:926–935. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kumavath R, Paul S, Pavithran H, Paul MK,
Ghosh P, Barh D and Azevedo V: Emergence of cardiac glycosides as
potential drugs: Current and future scope for cancer therapeutics.
Biomolecules. 11:12752021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Martey ON, He X, Xing H, Deng F, Feng S,
Li C and Shi X: Periplocymarin is a potential natural compound for
drug development: Highly permeable with absence of P-glycoprotein
efflux and cytochrome P450 inhibitions. Biopharm Drug Dispos.
35:195–206. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhao LM, Li L, Huang Y, Han LJ, Li D, Huo
BJ, Dai SL, Xu LY, Zhan Q and Shan BE: Antitumor effect of
periplocin in TRAIL-resistant gastric cancer cells via upregulation
of death receptor through activating ERK1/2EGR1 pathway. Mol
Carcinog. 58:1033–1045. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lohberger B, Wagner S, Wohlmuther J,
Kaltenegger H, Stuendl N, Leithner A, Rinner B, Kunert O, Bauer R
and Kretschmer N: Periplocin, the most anti-proliferative
constituent of Periploca sepium, specifically kills liposarcoma
cells by death receptor mediated apoptosis. Phytomedicine.
51:162–170. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
White E, Mehnert JM and Chan CS:
Autophagy, metabolism, and cancer. Clin Cancer Res. 21:5037–5046.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Schwartz LM: Autophagic cell death during
development-ancient and mysterious. Front Cell Dev Biol.
9:6563702021. View Article : Google Scholar
|
|
21
|
Lockshin RA and Zakeri Z: Apoptosis,
autophagy, and more. Int J Biochem Cell Biol. 36:2405–2419. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Levine B and Yuan J: Autophagy in cell
death: An innocent convict? J Clin Invest. 115:2679–2688. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Trenti A, Grumati P, Cusinato F, Orso G,
Bonaldo P and Trevisi L: Cardiac glycoside ouabain induces
autophagic cell death in non-small cell lung cancer cells via a
JNK-dependent decrease of Bcl-2. Biochem Pharmacol. 89:197–209.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Newman RA, Kondo Y, Yokoyama T, Dixon S,
Cartwright C, Chan D, Johansen M and Yang P: Autophagic cell death
of human pancreatic tumor cells mediated by oleandrin, a
lipid-soluble cardiac glycoside. Integr Cancer Ther. 6:354–364.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mariño G, Niso-Santano M, Baehrecke EH and
Kroemer G: Self-consumption: The interplay of autophagy and
apoptosis. Nat Rev Mol Cell Biol. 15:81–94. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang X, Zhou G, Liu C, Wei R, Zhu S, Xu Y,
Wu M and Miao Q: Acanthopanax versus 3-methyladenine ameliorates
sodium taurocholate-induced severe acute pancreatitis by inhibiting
the autophagic pathway in rats. Mediators Inflamm.
2016:83697042016. View Article : Google Scholar
|
|
27
|
Yang J, Wang B, Xu Q, Yang Y, Hou L, Yin
K, Guo Q, Hua Y, Zhang L, Li Y, et al: TMEM166 inhibits cell
proliferation, migration and invasion in hepatocellular carcinoma
via upregulating TP53. Mol Cell Biochem. 476:1151–1163. 2021.
View Article : Google Scholar
|
|
28
|
Liu HR, Peng XD, He HB, Wang YH, Li Y, He
GX, Liu YL, Li YL and Zeng CJ: Antiproliferative activity of the
total saponin of Solanum lyratum Thunb in Hela cells by inducing
apoptosis. Pharmazie. 63:836–842. 2008.PubMed/NCBI
|
|
29
|
Hyllienmark L and Brismar T: Effect of
metabolic inhibition on K+ channels in pyramidal cells of the
hippocampal CA1 region in rat brain slices. J Physiol. 496:155–164.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hyllienmark L and Brismar T: Effect of
hypoxia on membrane potential and resting conductance in rat
hippocampal neurons. Neuroscience. 91:511–517. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lin Z, Xing W, Gao C, Wang X, Qi D, Dai G,
Zhao W and Yan G: Inhibitory effect of vascular endothelial growth
factor on the slowly activating delayed rectifier potassium current
in guinea pig ventricular myocytes. J Am Heart Assoc.
7:e0077302018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang D, Gao JL, Zhao CY, Wang DN, Xing
XS, Hou XY, Wang SS, Liu Q and Luo Y: Cyclin G2 promotes the
formation of smooth muscle cells derived foam cells in
atherosclerosis via PP2A/NF-κB/LOX-1 pathway. Ann Transl Med.
9:4462021. View Article : Google Scholar
|
|
33
|
Scholzen T and Gerdes J: The Ki-67
protein: From the known and the unknown. J Cell Physiol.
182:311–322. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li X, Zhou Y, Zhang X, Cao X, Wu C and Guo
P: Cordycepin stimulates autophagy in macrophages and prevents
atherosclerotic plaque formation in ApoE(-/-) mice. Oncotarget.
8:94726–94737. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Medina-Ortiz K, López-Alvarez D, Navia F,
Hansen T, Fierro L and Castaño S: Identification of
Na(+)/K(+)-ATPase α/β isoforms in Rhinella marina tissues by RNAseq
and a molecular docking approach at the protein level to evaluate α
isoform affinities for bufadienolides. Comp Biochem Physiol A Mol
Integr Physiol. 254:1109062021. View Article : Google Scholar
|
|
36
|
Bers DM: Cardiac excitation-contraction
coupling. Nature. 415:198–205. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Liao YX, Yu HY, Lv JY, Cai YR, Liu F, He
ZM and He SS: Targeting autophagy is a promising therapeutic
strategy to overcome chemoresistance and reduce metastasis in
osteosarcoma. Int J Oncol. 55:1213–1222. 2019.PubMed/NCBI
|
|
38
|
Zhang XJ, Chen S, Huang KX and Le WD: Why
should autophagic flux be assessed? Acta Pharmacol Sin. 34:595–599.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Seranova E, Ward C, Chipara M, Rosenstock
TR and Sarkar S: In vitro screening platforms for identifying
autophagy modulators in mammalian cells. Methods Mol Biol.
1880:389–428. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
López M and Diéguez C: Cellular energy
sensors: AMPK and beyond. Mol Cell Endocrinol. 397:1–3. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Timm KN and Tyler DJ: The role of AMPK
activation for cardioprotection in doxorubicin-induced
cardiotoxicity. Cardiovasc Drugs Ther. 34:255–269. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hardie DG, Ross FA and Hawley SA: AMPK: A
nutrient and energy sensor that maintains energy homeostasis. Nat
Rev Mol Cell Biol. 13:251–262. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kang SA, Pacold ME, Cervantes CL, Lim D,
Lou HJ, Ottina K, Gray NS, Turk BE, Yaffe MB and Sabatini DM:
mTORC1 phosphorylation sites encode their sensitivity to starvation
and rapamycin. Science. 341:12365662013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Dyshlovoy SA: Blue-print autophagy in
2020: A critical review. Mar Drugs. 18:4822020. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Fozzard HA and Sheets MF: Cellular
mechanism of action of cardiac glycosides. J Am Coll Cardiol.
5:10A–15A. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Mijatovic T, Quaquebeke V, Delest B,
Debeir O, Darro F and Kiss R: Cardiotonic steroids on the road to
anti-cancer therapy. Biochim Biophys Acta. 1776:32–57.
2007.PubMed/NCBI
|
|
47
|
Škubník J, Pavlíčková VS, Psotová J and
Rimpelová S: Cardiac glycosides as autophagy modulators. Cells.
10:33412021. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Cheng CF, Lu IH, Tseng HW, Sun CY, Lin LT,
Kuo ZK, Pan IH and Ko CH: Antitumor effect of periplocin in
TRAIL-resistant human hepatocellular carcinoma cells through
downregulation of IAPs. Evid Based Complement Alternat Med.
2013:9580252013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Chao MW, Chen TH, Huang HL, Chang YW,
HuangFu WC, Lee YC, Teng CM and Pan SL: Lanatoside C, a cardiac
glycoside, acts through protein kinase Cδ to cause apoptosis of
human hepatocellular carcinoma cells. Sci Rep. 7:461342017.
View Article : Google Scholar
|
|
50
|
Xu ZW, Wang FM, Gao MJ, Chen XY, Shan NN,
Cheng SX, Mai X, Zala GH, Hu WL and Xu RC: Cardiotonic steroids
attenuate ERK phosphorylation and generate cell cycle arrest to
block human hepatoma cell growth. J Steroid Biochem Mol Biol.
125:181–191. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Rasheduzzaman M, Yin H and Park SY:
Cardiac glycoside sensitized hepatocellular carcinoma cells to
TRAIL via ROS generation, p38MAPK, mitochondrial transition, and
autophagy mediation. Mol Carcinog. 58:2040–2051. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Durmaz I, Guven EB, Ersahin T, Ozturk M,
Calis I and Cetin-Atalay R: Liver cancer cells are sensitive to
Lanatoside C induced cell death independent of their PTEN status.
Phytomedicine. 23:42–51. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Fujii T, Shimizu T, Yamamoto S, Funayama
K, Fujita K, Tabuchi Y, Ikari A, Takeshima H and Sakai H: Crosstalk
between Na(+), K(+)-ATPase and a volume-regulated anion channel in
membrane microdomains of human cancer cells. Biochim Biophys Acta
Mol Basis Dis. 1864:3792–3804. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Zhang HY, Xu WQ, Zheng YY, Omari-Siaw E,
Zhu Y, Cao X, Tong SS, Yu JN and Xu XM: Octreotide-periplocymarin
conjugate prodrug for improving targetability and anti-tumor
efficiency: Synthesis, in vitro and in vivo evaluation. Oncotarget.
7:86326–86338. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Gordy C and He YW: The crosstalk between
autophagy and apoptosis: Where does this lead? Protein Cell.
3:17–27. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Liu Y, Shoji-Kawata S, Sumpter RM Jr,
Ginet V, Zhang L, Posner B, Tran KA, Green DR, Xavier RJ, Shaw SY,
et al: Autosis is a Na+, K+-ATPase-regulated form of cell death
triggered by autophagy-inducing peptides, starvation, and
hypoxia-ischemia. Proc Natl Acad Sci USA. 110:20364–20371. 2013.
View Article : Google Scholar
|
|
57
|
Liu Y and Levine B: Autosis and autophagic
cell death: The dark side of autophagy. Cell Death Differ.
22:367–376. 2015. View Article : Google Scholar :
|
|
58
|
Zhang K, Chen J, Zhou H, Chen Y, Zhi Y,
Zhang B, Chen L, Chu X, Wang R and Zhang C: PU.1/microRNA-142-3p
targets ATG5/ATG16L1 to inactivate autophagy and sensitize
hepatocellular carcinoma cells to sorafenib. Cell Death Dis.
9:3122018. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Mukhopadhyay S, Panda PK, Sinha N, Das DN
and Bhutia SK: Autophagy and apoptosis: Where do they meet?
Apoptosis. 19:555–566. 2014. View Article : Google Scholar : PubMed/NCBI
|
